Effectiveness of a single COVID-19 mRNA vaccine dose in individuals with prior SARS-CoV-2 infection: a systematic review.

BACKGROUND

Based on high population immunity to SARS-CoV-2 from prior infection, vaccination, or both, in fall 2023, regulatory agencies globally authorized/approved a single mRNA XBB.1.5-adapted vaccine dose for individuals aged ≥5 years regardless of prior vaccination.

METHODS

We conducted a systematic review on vaccine effectiveness (VE) of a single COVID-19 mRNA dose in individuals with a history of prior infection compared to individuals who were (i) SARS-CoV-2 naïve, (ii) unvaccinated with prior infection, and (iii) vaccinated with >1 dose with or without prior infection. We searched MEDLINE and Embase for studies published January 2021-October 2023. Data were synthesized following Synthesis Without Meta-Analysis guidelines; bias was assessed using the Newcastle-Ottawa Scale. This study was registered with PROSPERO (CRD42023453257).

RESULTS

Eighteen studies were eligible. None of these studies reported bivalent or XBB.1.5-adapted VE, and none reported VE for immunocompromised populations or children aged <5 years. Among those with prior infection, a single mRNA dose increased protection by 8-71% against infection (during Omicron BA.1, BA.4/5, or XBB predominance), 39-67% against symptomatic infection (BA.1, BA.2, or BA.4/5), and 25-60% against hospitalization or hospitalization or death (BA.1). VE of one dose was comparable to two doses among those with prior infection, and higher than following two doses without prior infection.

CONCLUSIONS

A single dose of original mRNA COVID-19 vaccine provides similar protection to two doses for immunocompetent individuals aged ≥5 years in the current setting of high pre-existing immunity. This supports current recommendations for one dose to be given in advance of the respiratory season, regardless of history of infection or vaccination, with considerations for additional doses for certain populations including young children, older adults, and the immunocompromised.